SHARJAH-GOVERNMENT
6.6.2022 17:43:08 CEST | Business Wire | Press release
Around midnight on June 1, a hawksbill turtle landed on the Sir Bu Nair Island. It’s one of the many that began arriving three months ago to nest on the island, bringing the number of nests to more than 300 spread across 27 beaches. The hawksbill turtle lays between 90 to 110 eggs and quietly returns to the sea, leaving eggs to hatch in 50 to 70 days. Part of Sharjah, Sir Bu Nair is situated around 110 km north off the Emirate’s coast.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005699/en/
Declared a nature reserve by a government decree, the island is one of the most important breeding grounds for the endangered hawksbill turtle and features on the International Union for Conservation of Nature list.
The enchanting island, 13 sq km in size, is home to the sooty seagulls (Abu Sannin) and other terns who make thousands of nests in its red soil. Sharjah has strict laws in place to protect all living creatures on the island. Sir Bu Nair is rich in rare green sea turtles, deer, hedgehogs and reptiles. It has also recorded the discovery of the red coat fish.
Rich history
Sir Bu Nair Island has long been preserved in the region’s collective memory of historical events. The British established, during their presence in the region, the first railway in the Emirates, whose relics remain on one side of the beach under the sea.
The island is also known for the sweetness of its waters, which is also fabled to cure rare diseases.
Pottery vessels have been found on the island dating back to the Iron Age, i.e. about 3,500 years ago confirming the continuation of marine activity on the island during the past 35 centuries. There is a cemetery on the island that is known to contain the remains of a number of divers and miners, which represents an important stage in the history of the development of the people living on the banks of the Arabian Gulf.
Mars Island
The island is also known as Al-Jazirah Al-Hamra because of its red terrain and is often compared to the planet Mars. It’s rich in minerals, including sulfur and iron oxide. In the past, railways were used to transport minerals to ships for exporting abroad. Some mines survive to this day.
Known for its sandy beaches and its pristine waters, Sir Bu Nair and its surroundings are rich in coral and marine life, boasting more than 76 types of fish and 40 types of coral reefs.
Emirati poets have long described Sir Bu Nair as “the tear that fell in the waters of the Gulf.” The people of Sharjah have a strong affinity with the island thanks to their historical love of the sea and seafaring traditions. The island had been the seat of generations of pearldivers and fishermen.
International importance
The Sir Bu Nair reserve enjoys strategic global importance and is included in the International Convention on Wetlands because of its rich marine life. It’s included in the preliminary list of UNESCO World Heritage Sites, and an international agreement on the protection and management of sea turtles in the Indian Ocean and Southeast Asia.
HH Sheikh Sultan bin Ahmed Al Qasimi, Deputy Ruler of Sharjah, attended the 22nd Sir Bu Nair Festival, held on June 3-4 to highlight the island's environmental and touristic importance and consolidate the Emirati relationship with their environment and heritage.
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005699/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
